Indication: This product is only suitable for acromegaly and some digestive tract carcinoids and neuroendocrine tumors that require long-term administration. It is not suitable for short-term treatment of acute pancreatitis, upper gastrointestinal bleeding, etc.

Indication: It is used for active acromegaly that requires long-term octreotide treatment, such as increased serum growth hormone levels caused by postoperative growth hormone residual tumors, increased serum growth hormone levels in patients who have not yet achieved full therapeutic effect after external pituitary radiation therapy, and preoperative treatment of some patients who are not suitable for surgical treatment and newly diagnosed growth hormone-secreting adenomas.

Indication: It is used for active acromegaly that requires long-term octreotide treatment, such as increased serum growth hormone levels caused by postoperative growth hormone residual tumors, increased serum growth hormone levels in patients who have not yet achieved full therapeutic effect after external pituitary radiation therapy, and preoperative treatment of some patients who are not suitable for surgical treatment and newly diagnosed growth hormone-secreting adenomas.

Indication: 1. Emergency treatment of esophageal-gastric varicose bleeding caused by liver cirrhosis, combined with special treatment (such as endoscopic sclerotherapy); 2. Prevention of complications after pancreatic surgery; 3. Relieve symptoms and signs related to gastrointestinal endocrine tumors. There is sufficient evidence to show that this product is effective for the following tumors: carcinoid tumors with carcinoid syndrome; VIP tumors; glucagon tumors. The efficacy of this product for the following tumors is about 50% (so far, the cases treated with this product are limited): gastrinoma/Zollinger-Ellison syndrome, insulinoma, growth hormone releasing factor tumor; 3. Patients with acromegaly who have failed surgery, radiotherapy or dopamine receptor agonists.

Indication: Digestive system medications. Esophageal gastric venous bleeding, peptic ulcer and emergency ulcer, acute pancreatitis, prevention of complications after pancreatic surgery, gastrointestinal pancreatic endocrine tumors, acromegaly.

Indication: Digestive system medications. Esophageal gastric venous bleeding, peptic ulcer and emergency ulcer, acute pancreatitis, prevention of complications after pancreatic surgery, gastrointestinal pancreatic endocrine tumors, acromegaly.

Indication: Digestive system medications. Esophageal gastric venous bleeding, peptic ulcer and emergency ulcer, acute pancreatitis, prevention of complications after pancreatic surgery, gastrointestinal pancreatic endocrine tumors, acromegaly.

Indication: Sandostatin Injection is a somatostatin analogue indicated: Acromegaly 1. 1 Carcinoid Tumors 1. 2 Vasoactive Intestinal Peptide Tumors (VIPomas) 1. 3 Limitations of Use Improvement in clinical signs and symptoms, or reduction in tumor size or rate of growth, were not shown in clinical trials performed with Sandostatin Injection; these trials were not optimally designed to detect such effects. 4 Sandostatin Injection is indicated to reduce blood levels of growth hormone (GH) and insulin growth factor-1 (IGF-1; somatomedin C) in acromegaly patients who have had inadequate response to or cannot be treated with surgical resection, pituitary irradiation, and bromocriptine mesylate at maximally tolerated doses. Sandostatin Injection is indicated for treatment of severe diarrhea and flushing episodes associated with metastatic carcinoid tumors. Sandostatin Injection is indicated for the treatment of the profuse watery diarrhea associated with vasoactive intestinal peptide tumors (VIPomas)-secreting tumors. Improvement in clinical signs and symptoms, or reduction in tumor size or rate of growth, were not shown in clinical trials performed with Sandostatin Injection; these trials were not optimally designed to detect such effects.

Indication: Octreotide Acetate Injection is a somatostatin analogue indicated: Acromegaly 1. 1 Carcinoid Tumors 1. 2 Vasoactive Intestinal Peptide Tumors (VIPomas) 1. 3 Limitations of Use Improvement in clinical signs and symptoms, or reduction in tumor size or rate of growth, were not shown in clinical trials performed with Octreotide Acetate Injection; these trials were not optimally designed to detect such effects. 4 Octreotide Acetate Injection is indicated to reduce blood levels of growth hormone (GH) and insulin growth factor-1 (IGF-1; somatomedin C) in acromegaly patients who have had inadequate response to or cannot be treated with surgical resection, pituitary irradiation, and bromocriptine mesylate at maximally tolerated doses. Octreotide Acetate Injection is indicated for treatment of severe diarrhea and flushing episodes associated with metastatic carcinoid tumors. Octreotide Acetate Injection is indicated for the treatment of the profuse watery diarrhea associated with vasoactive intestinal peptide tumors (VIPomas)-secreting tumors. Improvement in clinical signs and symptoms, or reduction in tumor size or rate of growth, were not shown in clinical trials performed with Octreotide Acetate Injection; these trials were not optimally designed to detect such effects.

Indication: Hyperprolactinemia-Associated Dysfunctions hyperprolactinemia amenorrhea galactorrhea, infertility or hypogonadism prolactin-secreting adenomas, Reduction tumor size Acromegaly Parkinson’s Disease